article thumbnail

STAT+: Mid-year drug price hikes are back despite Inflation Reduction Act

STAT

At the start and halfway points of each year, many pharmaceutical companies raise drug prices to bolster revenue and reportedly fund new research. “It’s not just all selling new drugs,” said Juliette Cubanski, deputy director of the Program on Medicare Policy at Kaiser Family Foundation.

article thumbnail

NPPA monitors the prices of scheduled as well as non-scheduled medicines under DPCO, 2013

Express Pharma

According to the statement published by PIB, The National Pharmaceutical Pricing Authority (NPPA) is actively overseeing the pricing of both scheduled and non-scheduled medicines under the Drugs (Prices Control) Order, 2013 (DPCO, 2013).

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Mallinckrodt pays $260m to settle kickback, rebate fraud charges

pharmaphorum

The US government filed a complaint in the same year claiming Mallinckrodt unlawfully required Medicaid programmes to foot the bill for an increase in the price of Acthar Gel from $50 per vial to $28,000 per vial, according to the Department of Justice.

article thumbnail

July 2023 Newsletter

Safe Biologics

ASBM & GaBI Webinar on Medicare Price Negotiation Examines Impact on Innovation, Patient Access On July 26th, ASBM and the Generics and Biosimilars Initiative (GaBI) hosted a webinar entitled MEDICARE DRUG PRICE NEGOTIATIONS: Impact on Healthcare Development and Patient Access to Medicines. View the panel discussion here.

article thumbnail

New Report Provides Key Insights on 15 Years of Duchenne Patient-Reported Data

Putting Patients First Blog

Cardiac screening The use of echocardiogram and cardiac MRI in Duchenne increased across most age groups when comparing the time periods 2007-2012, 2013-2017, and 2018-2022 with some age groups having statistical significance. The average age at loss of ambulation for registrants who never used corticosteroids was 10.5

article thumbnail

How eligible patient numbers affect price of rare disease drugs in France

pharmaphorum

Having recently assessed the relationship between drug price and prevalence of non-oncology rare diseases, CRA’s Life Sciences Practice team explores in greater depth the situation for these orphan drugs in France in this final article of a three-part series. Influence of ATUc programme on drug pricing.

article thumbnail

December 2023 Newsletter

Safe Biologics

Beginning in 2013, all 50 states and Puerto Rico enacted legislation that allows for pharmacy-level, automatic substitution only for biosimilars given interchangeable status based on additional data provided to the FDA that demonstrates safe switching. Proposing to change this standard in the U.S.